Holen Sie sich die Stockscreener-App
248.95
0.84%
2.07
Handel nachbörslich:
247.65
-1.30
-0.52%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$246.88
Offen:
$247.54
24-Stunden-Volumen:
1.60M
Relative Volume:
1.55
Marktkapitalisierung:
$36.45B
Einnahmen:
$5.15B
Nettoeinkommen (Verlust:
$1.40B
KGV:
26.18
EPS:
9.5082
Netto-Cashflow:
$1.65B
1W Leistung:
-3.96%
1M Leistung:
-10.64%
6M Leistung:
+3.75%
1J Leistung:
+1.91%
1-Tages-Spanne:
$243.12
$252.15
1-Wochen-Bereich:
$239.41
$264.00
52-Wochen-Spanne:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Vergleichen Sie RMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
248.95 | 36.04B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
ISRG
Intuitive Surgical Inc
|
544.21 | 189.40B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
177.30 | 51.22B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
ALC
Alcon Inc
|
73.88 | 36.53B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
WST
West Pharmaceutical Services Inc
|
279.78 | 20.29B | 2.96B | 487.70M | 344.00M | 6.6758 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
Key resistance and support levels for ResMed Inc.July 2025 News Drivers & Daily Technical Forecast Reports - newser.com
Using RSI to spot recovery in ResMed Inc.Layoff News & Growth Focused Stock Reports - newser.com
Morgans Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
ResMed Inc. Officer Plans Sale of 3,000 Shares - MSN
Resmed Inc Reports Changes in CDI and Security Issuance for October 2025 - TipRanks
[144] RESMED INC SEC Filing - Stock Titan
Is ResMed Inc. (Common Stock) (RMEA) stock in buy zone after pullbackRate Hike & Long-Term Safe Investment Ideas - newser.com
How to build a dashboard for ResMed Inc. stock2025 Earnings Impact & Technical Analysis for Trade Confirmation - newser.com
Will ResMed Inc. (RME) stock profit from automation waveQuarterly Profit Report & Risk Managed Investment Strategies - newser.com
How ResMed Inc. (Common Stock) (RMEA) stock reacts to fiscal policiesQuarterly Trade Report & Breakout Confirmation Alerts - newser.com
ResMed Inc. stock momentum explainedDip Buying & Fast Gain Stock Tips - newser.com
Will earnings trigger a reversal in ResMed Inc.Market Performance Summary & Low Risk High Win Rate Stock Picks - newser.com
RMD: Baird Lowers Price Target for ResMed to $300 While Maintaining Outperform Rating | RMD Stock News - GuruFocus
What to do if you’re stuck in ResMed Inc.Oil Prices & AI Forecast Swing Trade Picks - newser.com
Will ResMed Inc. (Common Stock) (RMEA) stock deliver stable dividendsJuly 2025 Intraday Action & Capital Efficient Trading Techniques - newser.com
ResMed Inc. $RMD Shares Sold by Hunter Associates Investment Management LLC - MarketBeat
Is ResMed Inc. (RME) stock a buy on weakness2025 Investor Takeaways & Expert Approved Momentum Ideas - newser.com
Is ResMed Inc. reversing from oversold territoryMarket Growth Report & Smart Allocation Stock Tips - newser.com
Harel Insurance Investments & Financial Services Ltd. Raises Holdings in ResMed Inc. $RMD - MarketBeat
W.G. Shaheen & Associates DBA Whitney & Co Increases Stock Position in ResMed Inc. $RMD - MarketBeat
Welch & Forbes LLC Grows Stake in ResMed Inc. $RMD - MarketBeat
Regal Partners Ltd Purchases New Shares in ResMed Inc. $RMD - MarketBeat
Why analysts remain bullish on ResMed Inc. stockJuly 2025 Drop Watch & Capital Protection Trading Alerts - newser.com
Hantz Financial Services Inc. Has $307,000 Stock Holdings in ResMed Inc. $RMD - MarketBeat
Will ResMed Inc. (Common Stock) (RMEA) stock see valuation expansionPortfolio Update Summary & Free Fast Gain Swing Trade Alerts - newser.com
William Blair Has Pessimistic Outlook of ResMed Q2 Earnings - MarketBeat
Can swing trading help recover from ResMed Inc. lossesMarket Activity Summary & Daily Technical Stock Forecast Reports - newser.com
Why ResMed Inc. (RME) stock remains stableTrade Entry Report & Risk Adjusted Swing Trade Ideas - newser.com
Will ResMed Inc. outperform the market2025 Major Catalysts & Safe Capital Growth Trade Ideas - newser.com
ResMed Inc. Files Quarterly Report, Affirms Market Position - MSN
Will ResMed Inc. stock benefit from mergersOil Prices & Weekly Watchlist for Consistent Profits - newser.com
How ResMed Inc. (Common Stock) (RMEA) stock performs in volatility spikesDividend Hike & Smart Allocation Stock Reports - newser.com
ResMed Inc. Reports Strong Q1 Earnings Amid Growth Challenges - MSN
What candlestick patterns are forming on ResMed Inc.Bond Market & Smart Investment Allocation Insights - newser.com
ResMed: Q1 result 2026 - intelligentinvestor.com.au
How supply shortages influence ResMed Inc. (Common Stock) (RMEA) stockM&A Rumor & Consistent Growth Stock Picks - newser.com
Is ResMed Inc. stock oversold or undervaluedJuly 2025 Breakouts & Long-Term Safe Investment Ideas - newser.com
Why ResMed Inc. stock benefits from AI revolutionTrade Risk Summary & Weekly High Return Stock Opportunities - newser.com
Resmed Stock Up on Q1 Earnings & Revenue Beat, Margins Expand - MSN
Is ResMed Inc. stock vulnerable to regulatory risks2025 Trade Ideas & Real-Time Chart Breakout Alerts - newser.com
Pinnacle Associates Ltd. Sells 3,354 Shares of ResMed Inc. $RMD - MarketBeat
Spire Wealth Management Increases Stake in ResMed Inc. $RMD - MarketBeat
Will ResMed Inc. stock deliver consistent dividends2025 Earnings Surprises & Stepwise Trade Signal Guides - newser.com
Oppenheimer Asset Management Inc. Cuts Stock Position in ResMed Inc. $RMD - MarketBeat
Bessemer Group Inc. Has $838,000 Stock Position in ResMed Inc. $RMD - MarketBeat
Published on: 2025-11-02 03:04:22 - newser.com
ResMed Inc. (RMD.AX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
ResMed, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
ResMed (RMD) Margin Beat Reinforces Quality Earnings Narrative - Sahm
ResMed (NYSE:RMD) Price Target Raised to $303.00 - MarketBeat
ResMed outlines high single-digit growth targets for mask segment as new fabric mask launches drive innovation - MSN
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.01%
0.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):